Protalix BioTherapeutics, Inc.
PLX
$1.98
$0.021.02%
AMEX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 15.33M | -6.60M | 5.39M | 6.28M | 3.91M |
| Total Depreciation and Amortization | 1.52M | 1.47M | 1.41M | 1.37M | 1.33M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3.96M | 3.25M | 2.48M | 4.02M | 3.31M |
| Change in Net Operating Assets | -5.72M | -10.10M | -19.32M | -13.86M | -9.11M |
| Cash from Operations | 15.09M | -11.99M | -10.03M | -2.20M | -572.00K |
| Capital Expenditure | -2.09M | -1.64M | -1.66M | -1.25M | -990.00K |
| Sale of Property, Plant, and Equipment | -- | -- | 0.00 | 3.00K | 3.00K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 4.26M | -728.00K | -14.91M | 5.50M | 5.50M |
| Cash from Investing | 2.17M | -2.37M | -16.57M | 4.26M | 4.52M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | 0.00 | -20.42M | -20.42M |
| Issuance of Common Stock | 4.40M | 9.33M | 12.81M | 12.81M | 8.70M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 4.40M | 9.33M | 12.81M | -7.61M | -11.72M |
| Foreign Exchange rate Adjustments | -116.00K | -47.00K | 38.00K | 48.00K | 24.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 21.54M | -5.08M | -13.76M | -5.50M | -7.75M |